Effect of a Short Nap During the Night Shift of Healthcare Workers on Endothelial Function (NCT05955729) | Clinical Trial Compass
CompletedNot Applicable
Effect of a Short Nap During the Night Shift of Healthcare Workers on Endothelial Function
France80 participantsStarted 2024-02-19
Plain-language summary
Night shift work is well known to cause health disruption in short and long term. It has been reported that among healthcare workers, nurses slept less than 6 h/24h. Consequences of such short sleep duration has been associated to long term issues such as endothelial dysfunction associated with cardiovascular diseases, arterial hypertension and type 2 diabetes. Countermeasures such as nap at work has potential effects on reducing the prevalence of cardiovascular diseases. However, to our knowledge, no studies have objectively investigated the effects of napping on endothelial function in a longitudinal design. Therefore, this study aims to investigate the effect of a 30 minutes on-duty nap during night work for 12 weeks on caregivers endothelial dysfunction.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Being a paramedical caregiverr (nurse or care assistant) at Saint-Etienne University Hospital
* Be aAged between 18 and 65
* Working at least 80% of a full-time equivalent post
* Working 12-hour shifts (day/night) in continuous care services
* Being affiliated or entitled under a social security scheme
* Havinge received informed information about the study and have co-signed, with the investigator, a consent to participate in the study
Exclusion Criteria:
* Have made a tTrans meridian journey in the last month prior to the study
* Have a mMedically diagnosed sleep disorder such asof the hypersomnia or insomnia type
* Have a diagnosed and treated mental pathology
* Usually take a nap in the workplace in a quiet room
* Be pregnant or breastfeeding
* Have medically diagnosed neurovascular or neuromuscular pathologies
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evolution of reactive hyperemia index (RHI)
Timeframe: Change between week 1 and 12
Trial details
NCT IDNCT05955729
SponsorCentre Hospitalier Universitaire de Saint Etienne